Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
Status:
Completed
Trial end date:
2013-10-09
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well axitinib works in treating patients with
high-risk prostate cancer before undergoing surgery. Axitinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving axitinib before surgery
may make the tumor smaller and reduce the amount of normal cells that have to be removed